Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROVOCHOLINE vs EVOXAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
FDA: Diagnosis of bronchial airway hyperreactivity in subjects without clinically apparent asthma.,Off-label: Treatment of xerostomia, glaucoma.
Treatment of dry mouth symptoms in patients with Sjögren's syndrome,Off-label: Management of radiation-induced xerostomia
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
30 mg orally three times daily.
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Primarily metabolized by acetylcholinesterase.
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes N-oxidation and hydroxylation.
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
Very low protein binding (<5%). Does not significantly bind to albumin or other plasma proteins.
Approximately 50-60% bound to plasma proteins, primarily albumin.
Approximately 0.1-0.2 L/kg. Small Vd indicates limited extravascular distribution, consistent with a quaternary ammonium compound that does not readily cross cell membranes or the blood-brain barrier.
Volume of distribution is approximately 6 L/kg, indicating extensive distribution into tissues beyond plasma water.
Subcutaneous: approximately 90-100%. Oral: Very low (<2%) due to extensive presystemic metabolism by cholinesterases in the gastrointestinal tract and liver. Not administered orally. Inhalation: Variable, but effective locally; systemic absorption is minimal.
Oral bioavailability is approximately 30% due to extensive first-pass metabolism.
No specific guidelines; use caution in severe renal impairment.
For GFR <30 m L/min: not recommended due to increased systemic exposure.
No specific guidelines; use caution in severe hepatic impairment.
No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
Safety and efficacy not established; use not recommended.
Safety and efficacy not established; no recommended dose.
Use with caution due to potential for increased sensitivity and comorbidities; consider starting at lower end of dosing range.
No specific dose adjustment; monitor for increased anticholinergic effects due to age-related reduced clearance.
Severe asthma or wheezing; administration to patients with asthma can cause fatal bronchospasm.
None.
Should be administered only by trained personnel; emergency resuscitative equipment must be immediately available; may cause bronchoconstriction, bradycardia, hypotension; use caution in patients with cardiovascular disease, epilepsy, hyperthyroidism, peptic ulcer, urinary obstruction.
Cardiovascular effects: May cause bradycardia, AV block, hypotension; use caution in patients with cardiovascular disease.,Pulmonary effects: Can exacerbate asthma, chronic bronchitis, or COPD due to increased bronchial secretions.,Ophthalmic effects: May impair night vision or cause visual disturbances; caution when driving at night.,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Caution in moderate to severe hepatic disease.,Potential for sweating and dehydration: Monitor fluid intake.,Drug interactions: Concomitant use with beta-blockers or other cholinergic agents may increase risk of bradycardia.
Asthma, COPD, severe cardiac disease, recent myocardial infarction, hypotension, hypertension, hyperthyroidism, epilepsy, Parkinson's disease, peptic ulcer, gastrointestinal or urinary obstruction, pregnancy (Category C).
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis,Hypersensitivity to cevimeline or any component,Concurrent use with certain anticholinergics (e.g., atropine) due to antagonistic effects
Avoid caffeine-containing foods and beverages (coffee, tea, chocolate, cola) for at least 6 hours prior to bronchial challenge testing as they can affect airway reactivity.
No significant food interactions; may be taken with or without food. However, high-fat meals may delay absorption but not overall effect.
Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, bronchial provocation testing is generally avoided during pregnancy due to potential maternal hypoxia and fetal distress. First trimester: theoretical risk from maternal hypoxia; second and third trimesters: risk of preterm labor and fetal hypoxia if severe bronchospasm occurs.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variations at doses 2-4 times the maximum recommended human dose. First trimester: Potential risk, use only if benefit justifies risk. Second trimester: Limited data, avoid unless necessary. Third trimester: No specific fetal risks identified, but monitor for maternal cholinergic effects.
No human data on excretion in breast milk. Methacholine is rapidly hydrolyzed by plasma cholinesterases; systemic absorption after inhalation is minimal. M/P ratio is unknown. Caution is advised, but risk to nursing infant is likely low given rapid metabolism and low bioavailability.
Unknown if excreted in human breast milk. M/P ratio not available. Caution advised due to potential for cholinergic side effects in nursing infants. Consider discontinuing nursing or drug, taking into account importance of drug to mother.
No specific dosing adjustments are recommended for methacholine challenge testing during pregnancy; however, the test is typically deferred due to potential risks. If conducted, start with lowest concentration (0.025 mg/m L) and titrate cautiously with close monitoring due to possible increased sensitivity of airway receptors and altered pharmacokinetics (increased plasma volume and decreased cholinesterase activity may prolong effects).
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter drug absorption and metabolism; however, no established dose adjustments. Start at lowest effective dose (30 mg three times daily) and titrate based on response and tolerability. Monitor for reduced efficacy or increased toxicity due to pregnancy-induced changes.
Provocholine (methacholine chloride) is used for bronchial challenge testing to diagnose airway hyperreactivity in patients with suspected asthma but normal baseline spirometry. Administer with a nebulizer in increasing concentrations (0.025 to 25 mg/m L). Contraindicated in patients with FEV1 < 60% predicted, recent myocardial infarction, severe hypertension, or known hypersensitivity. Emergency resuscitation equipment must be available. Monitor for bronchospasm, oxygen desaturation, and treat with short-acting beta-agonists if needed.
EVOXAC (cevimeline) is a cholinergic agonist used primarily for xerostomia in Sjögren's syndrome; a key pearl is to avoid concurrent use with other parasympathomimetics due to additive effects. Monitor for excessive sweating, bradycardia, and bronchospasm, especially in patients with asthma or COPD. Contraindicated in uncontrolled asthma, iritis, and angle-closure glaucoma. Dose reduction may be required in renal impairment.
This test measures how sensitive your airways are to a substance that can cause narrowing.,You will inhale increasing doses of methacholine through a nebulizer while your breathing is tested.,Inform your doctor if you have asthma, recent heart attack, high blood pressure, or are pregnant.,Do not use caffeine or tobacco for at least 6 hours before the test.,Avoid using inhaler medications (e.g., albuterol) for 8-12 hours before the test as directed.,You may experience coughing, chest tightness, or shortness of breath during the test.,The test is stopped if your breathing drops significantly, and medication will be given to reverse effects.
Take exactly as prescribed, usually three times daily with or without food.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause blurred vision or dizziness.,Report excessive sweating, abdominal cramps, slow heart rate, or difficulty breathing to your healthcare provider immediately.,Do not use with other medications that increase saliva or tear production without consulting your doctor.,Store at room temperature away from moisture and heat.
"The serum concentration of Bupropion can be increased when it is combined with Choline."
"The therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline."
"The serum concentration of Choline can be increased when it is combined with Tipiracil."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROVOCHOLINE vs EVOXAC, answered by our medical review team.
PROVOCHOLINE is a Cholinergic Agonist that works by Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.. EVOXAC is a Cholinergic Agonist that works by Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROVOCHOLINE and EVOXAC depend on the specific clinical indication. These are both Cholinergic Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROVOCHOLINE is: Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.. The standard adult dose of EVOXAC is: 30 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROVOCHOLINE and EVOXAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROVOCHOLINE is classified as Category C. Pregnancy Category C. Based on animal studies and limited human data, PROVOCHOLINE (methacholine) is not expected to increase the risk of major congenital malformations. However, b. EVOXAC is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.